136 related articles for article (PubMed ID: 37034685)
1. Targeting wild-type IDH1 enhances chemosensitivity in pancreatic cancer.
Zarei M; Hajihassani O; Hue JJ; Graor HJ; Rothermel LD; Winter JM
bioRxiv; 2023 Mar; ():. PubMed ID: 37034685
[TBL] [Abstract][Full Text] [Related]
2. Wild-type IDH1 inhibition enhances chemotherapy response in melanoma.
Zarei M; Hajihassani O; Hue JJ; Graor HJ; Loftus AW; Rathore M; Vaziri-Gohar A; Asara JM; Winter JM; Rothermel LD
J Exp Clin Cancer Res; 2022 Sep; 41(1):283. PubMed ID: 36153582
[TBL] [Abstract][Full Text] [Related]
3. Limited nutrient availability in the tumor microenvironment renders pancreatic tumors sensitive to allosteric IDH1 inhibitors.
Vaziri-Gohar A; Cassel J; Mohammed FS; Zarei M; Hue JJ; Hajihassani O; Graor HJ; Srikanth YVV; Karim SA; Abbas A; Prendergast E; Chen V; Katayama ES; Dukleska K; Khokhar I; Andren A; Zhang L; Wu C; Erokwu B; Flask CA; Zarei M; Wang R; Rothermel LD; Romani AMP; Bowers J; Getts R; Tatsuoka C; Morton JP; Bederman I; Brunengraber H; Lyssiotis CA; Salvino JM; Brody JR; Winter JM
Nat Cancer; 2022 Jul; 3(7):852-865. PubMed ID: 35681100
[TBL] [Abstract][Full Text] [Related]
4. IDH1 inhibition potentiates chemotherapy efficacy in pancreatic cancer.
Zarei M; Hajihassani O; Hue JJ; Loftus AW; J Graor H; Nakazzi F; Naji P; Boutros CS; Uppin V; Vaziri-Gohar A; Shalaby A; Asara JM; Rothermel LD; Brody JR; Winter JM
Cancer Res; 2024 Jun; ():. PubMed ID: 38843355
[TBL] [Abstract][Full Text] [Related]
5. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Abou-Alfa GK; Macarulla T; Javle MM; Kelley RK; Lubner SJ; Adeva J; Cleary JM; Catenacci DV; Borad MJ; Bridgewater J; Harris WP; Murphy AG; Oh DY; Whisenant J; Lowery MA; Goyal L; Shroff RT; El-Khoueiry AB; Fan B; Wu B; Chamberlain CX; Jiang L; Gliser C; Pandya SS; Valle JW; Zhu AX
Lancet Oncol; 2020 Jun; 21(6):796-807. PubMed ID: 32416072
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies.
Chen Y; Nagaraja NV; Fan B; Utley L; Lemieux RM; Popovici-Muller J; Dang L; Kim H; Yan L; Su SM; Biller SA; Yang H
Drug Metab Dispos; 2021 Oct; 49(10):870-881. PubMed ID: 34321251
[TBL] [Abstract][Full Text] [Related]
7. Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma.
Corrigan L; Lowery M
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):475-481. PubMed ID: 33836133
[No Abstract] [Full Text] [Related]
8. Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.
DiNardo CD; Stein AS; Stein EM; Fathi AT; Frankfurt O; Schuh AC; Döhner H; Martinelli G; Patel PA; Raffoux E; Tan P; Zeidan AM; de Botton S; Kantarjian HM; Stone RM; Frattini MG; Lersch F; Gong J; Gianolio DA; Zhang V; Franovic A; Fan B; Goldwasser M; Daigle S; Choe S; Wu B; Winkler T; Vyas P
J Clin Oncol; 2021 Jan; 39(1):57-65. PubMed ID: 33119479
[TBL] [Abstract][Full Text] [Related]
9. Ivosidenib: A Review in Advanced Cholangiocarcinoma.
Frampton JE
Target Oncol; 2023 Nov; 18(6):973-980. PubMed ID: 37855990
[TBL] [Abstract][Full Text] [Related]
10. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.
Zhu AX; Macarulla T; Javle MM; Kelley RK; Lubner SJ; Adeva J; Cleary JM; Catenacci DVT; Borad MJ; Bridgewater JA; Harris WP; Murphy AG; Oh DY; Whisenant JR; Lowery MA; Goyal L; Shroff RT; El-Khoueiry AB; Chamberlain CX; Aguado-Fraile E; Choe S; Wu B; Liu H; Gliser C; Pandya SS; Valle JW; Abou-Alfa GK
JAMA Oncol; 2021 Nov; 7(11):1669-1677. PubMed ID: 34554208
[TBL] [Abstract][Full Text] [Related]
11. Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia.
Pasquier F; Lecuit M; Broutin S; Saada S; Jeanson A; Penard-Lacronique V; de Botton S
Drugs Today (Barc); 2020 Jan; 56(1):21-32. PubMed ID: 32055803
[TBL] [Abstract][Full Text] [Related]
12. Recent advances of IDH1 mutant inhibitor in cancer therapy.
Tian W; Zhang W; Wang Y; Jin R; Wang Y; Guo H; Tang Y; Yao X
Front Pharmacol; 2022; 13():982424. PubMed ID: 36091829
[TBL] [Abstract][Full Text] [Related]
13. Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions.
Lavacchi D; Caliman E; Rossi G; Buttitta E; Botteri C; Fancelli S; Pellegrini E; Roviello G; Pillozzi S; Antonuzzo L
Pharmacol Ther; 2022 Sep; 237():108170. PubMed ID: 35296436
[TBL] [Abstract][Full Text] [Related]
14. Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To Date.
Uson Junior PLS; Borad MJ
Cancer Manag Res; 2023; 15():1025-1031. PubMed ID: 37746315
[TBL] [Abstract][Full Text] [Related]
15. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.
Lowery MA; Burris HA; Janku F; Shroff RT; Cleary JM; Azad NS; Goyal L; Maher EA; Gore L; Hollebecque A; Beeram M; Trent JC; Jiang L; Fan B; Aguado-Fraile E; Choe S; Wu B; Gliser C; Agresta SV; Pandya SS; Zhu AX; Abou-Alfa GK
Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):711-720. PubMed ID: 31300360
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors.
Fan B; Mellinghoff IK; Wen PY; Lowery MA; Goyal L; Tap WD; Pandya SS; Manyak E; Jiang L; Liu G; Nimkar T; Gliser C; Prahl Judge M; Agresta S; Yang H; Dai D
Invest New Drugs; 2020 Apr; 38(2):433-444. PubMed ID: 31028664
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence.
Stemer G; Rowe JM; Ofran Y
Blood Lymphat Cancer; 2021; 11():41-54. PubMed ID: 34188585
[TBL] [Abstract][Full Text] [Related]
18. Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma.
Tap WD; Villalobos VM; Cote GM; Burris H; Janku F; Mir O; Beeram M; Wagner AJ; Jiang L; Wu B; Choe S; Yen K; Gliser C; Fan B; Agresta S; Pandya SS; Trent JC
J Clin Oncol; 2020 May; 38(15):1693-1701. PubMed ID: 32208957
[TBL] [Abstract][Full Text] [Related]
19. Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.
Popovici-Muller J; Lemieux RM; Artin E; Saunders JO; Salituro FG; Travins J; Cianchetta G; Cai Z; Zhou D; Cui D; Chen P; Straley K; Tobin E; Wang F; David MD; Penard-Lacronique V; Quivoron C; Saada V; de Botton S; Gross S; Dang L; Yang H; Utley L; Chen Y; Kim H; Jin S; Gu Z; Yao G; Luo Z; Lv X; Fang C; Yan L; Olaharski A; Silverman L; Biller S; Su SM; Yen K
ACS Med Chem Lett; 2018 Apr; 9(4):300-305. PubMed ID: 29670690
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic Reprogramming of Autophagy Drives Mutant IDH1 Glioma Progression and Response to Radiation.
Núñez FJ; Banerjee K; Mujeeb AA; Mauser A; Tronrud CE; Zhu Z; Taher A; Kadiyala P; Carney SV; Garcia-Fabiani MB; Comba A; Alghamri MS; McClellan BL; Faisal SM; Nwosu ZC; Hong HS; Qin T; Sartor MA; Ljungman M; Cheng SY; Appelman HD; Lowenstein PR; Lahann J; Lyssiotis CA; Castro MG
bioRxiv; 2024 Mar; ():. PubMed ID: 38559270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
